Inovio Pharmaceuticals reports $48.4M cash and investments as of Sept 30, 2026

Item 2.02

Results of Operations and Financial Condition.

Inovio Pharmaceuticals, Inc. (the "Company") is providing the following financial information. As of September 30, 2026, the Company estimates that its cash, cash equivalents and short-term investments were approximately $48.4 million.¹

The cash, cash equivalents and short-term investments information above is based on preliminary unaudited information and management estimates for the quarter ended September 30, 2026², is not a comprehensive statement of the Company's financial results as of and for the quarter ended September 30, 2026, and is subject to completion of the Company's financial closing procedures.³

The preliminary financial data included in this current report has been prepared by, and is the responsibility of, the Company's management. Ernst & Young LLP has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data.^{4 4}Accordingly, Ernst & Young LLP does not express an opinion or any other form of assurance with respect thereto.⁴

The information in this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended⁶, or otherwise subject to the liabilities of that Section. The information in this Current Report on Form 8-K shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "expects," "intends," "projects," "plans," and "future" or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements regarding the preliminary estimate of the Company's cash, cash equivalents and short-term investments as of September 30, 2026. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including, without limitation, the Company's actual results for the quarter ended September 30, 2026 may differ materially from the Company's preliminary estimates⁵ as a result of changes to assumptions and estimates, the completion of review of internal controls over financial reporting or other quarter-end and year-end procedures. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding the Company's business are described in detail in its SEC filings, including, in the section of the prospectus supplement titled "Risk Factors," filed with the SEC on November 5, 2026, the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and the Company's Annual Report on Form 10-K for the year ended December 31, 2025, which are available on the SEC's website at www.sec.gov. Additional information will be made available in other filings that the Company makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these statements except as may be required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INOVIO PHARMACEUTICALS, INC.

Date: November 5, 2026

By:

/s/ Peter Kies⁷

Peter Kies

Chief Financial Officer⁷